There is really no good reason for this stock to be so oversold. I
think this is a rare opportunity to buy a company with these
fundamentals at as low as $4.20 per share. The fundamentals are
strong. They remain strong. What instigated this downturn since
September has been the publication of a research report by infamous
short-seller Manual Asensio, trying to raise questions about CEO Tony
Liu's undisclosed ties to other foreign companies. AOB has addressed
this issue on their website http://www.bioaobo.com and sought a cease
and desist order against Asensio. Asensio is not exactly an upstanding
character. Look him up. So I think the growth prospects for this
budding Chinese pharmaceutical/nutriceutical remain very strong, and I
think this is the last downturn we're going to see as the result of
reports issued by Asensio. This chart is extremely oversold by any
reasonable medium-to-long term measure, and you should buy before you
miss the bottom.